Torl BioTherapeutics’ $158 million Series B-2 financing will finance clinical testing of its pipeline of antibody drug conjugates in development for various types of cancer. Neuroscience and immunology are among the therapeutic areas represented in our roundup of other recent biotech financings.
The post Another ADC Developer Lands a Mega Round of Financing for Cancer Clinical Trials appeared first on MedCity News.
Leave a comment